COL17A1 and Parkinson disease: Although BIOCHIP, BP180 NC16A ELISA, BP230 ELISA, and immunoblotting with the extracellular matrix of cultured human keratinocytes were used to detect anti-BMZ antibodies in MS and Parkinson’s disease patients, MS and Parkinson’s disease showed no significant increased prevalence of BP autoantibodies (42).